CAJ | 학술논문

目的探讨脐带间充质干细胞(UC-MSCs)对MRL/lpr狼疮鼠的治疗作用.方法 24只18周龄雌性MRL/lpr小鼠,分为3组:UC-MSCs 1次治疗组(G1)、UC-MSCs 3次治疗组(G2)、对照组(G3).观察体质量,考马斯亮蓝法榆测尿蛋白定量(24 h),酶联免疫吸附法(ELISA)检测抗双链DNA(dsDNA)抗体水平,观察肾脏、肺病理改变.结果 ①尿蛋白定量(24 h)25周时G1组(2.3±1.9)mg和G2组(1.8±1.4)mg显著低于对照组(3.8±2.1)mg(P<0.05),27周时G1组(2.5±1.5)mg和G2组(1.9±1.2)mg也显著低于对照组(5.4±2.4)mg(P<0.01).②24周时治疗组体质量显著高于对照组(P<0.05),29周时血清肌酐G1组(7.2±3.2)μmol/L和G2组(6.2±2.8)μmol/L显著低于对照组(12.5±2.3)μmol/L(P<0.05).③移植1周时,抗dsDNA抗体滴度G1组(46±11)×102 U/ml和G2组(49±43)×102 U/ml显著低于对照组(99±42)×102 U/ml(P<0.05);29周时G2组(36±15)×102 U/ml显著低于对照组(68±32)×102 U/ml.④肾小球新月体形成率G1组(0.12±0.07)和G2组(0.08±0.02)显著低于对照组(0.20±0.06)(P<0.05),G2组较G1组显著减低(P<0.05).⑤间质性肺炎G1组和G2组较对照组减轻.结论 UC-MSCs对MRL/lpr狼疮鼠有显著疗效,安全且无排斥反应.
목적 탐토제대간충질간세포(UC-MSCs)대MRL/lpr랑창서적치료작용.방법 24지18주령자성MRL/lpr소서,분위3조:UC-MSCs 1차치료조(G1)、UC-MSCs 3차치료조(G2)、대조조(G3).관찰체질량,고마사량람법유측뇨단백정량(24 h),매련면역흡부법(ELISA)검측항쌍련DNA(dsDNA)항체수평,관찰신장、폐병리개변.결과 ①뇨단백정량(24 h)25주시G1조(2.3±1.9)mg화G2조(1.8±1.4)mg현저저우대조조(3.8±2.1)mg(P<0.05),27주시G1조(2.5±1.5)mg화G2조(1.9±1.2)mg야현저저우대조조(5.4±2.4)mg(P<0.01).②24주시치료조체질량현저고우대조조(P<0.05),29주시혈청기항G1조(7.2±3.2)μmol/L화G2조(6.2±2.8)μmol/L현저저우대조조(12.5±2.3)μmol/L(P<0.05).③이식1주시,항dsDNA항체적도G1조(46±11)×102 U/ml화G2조(49±43)×102 U/ml현저저우대조조(99±42)×102 U/ml(P<0.05);29주시G2조(36±15)×102 U/ml현저저우대조조(68±32)×102 U/ml.④신소구신월체형성솔G1조(0.12±0.07)화G2조(0.08±0.02)현저저우대조조(0.20±0.06)(P<0.05),G2조교G1조현저감저(P<0.05).⑤간질성폐염G1조화G2조교대조조감경.결론 UC-MSCs대MRL/lpr랑창서유현저료효,안전차무배척반응.
Objective To investigate the efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in the treatment of the MRL/lpr mice. Methods Twenty four 18-week-old MRL/lpr female mice were divided into 3 groups:group 1 (G1) were transplanted with 1×106 UC- MSCs through caudal vein, group 2 (G2) were transplanted with 1×106 UC- MSCs three times and group 3 (G3) were treated with 0.5 ml normal saline as controls. Enzyme linked immunosorbent assay (ELISA) was used to measure the levels of serum anti-dsDNA antibodies. Twenty-four hours proteinuria and body weight were assessed every two weeks. The histopathology changes of the kidneys and lungs were observed. Results ① At the 25th weeks, the 24 hours proteinuria in group G1 (2.3±1.9) mg and G2 (1.8±1.4) mg was decreased than that in the control group (3.8±2.1) mg (P<0.05), and at the 27th weeks, that of groups G1 (2.5±1.5) mg and G2 (1.9±1.2) mg was also significantly decreased than in the control group (5.4±2.4) mg (P<0.01); ② From the 24th week, the body weight of groups G1 and G2 increased significantly than that of the control group (P< 0.05). At week 29, serum creatinine decreased significantly in both groups G1 (7.2±3.2) μmol/L and G2 (6.2±2.8) μmol/L than in the control group (12.5±2.3 ) μmol/L (P<0.05); ③One week after transplantation, the levels of anti-dsDNA antibodies in group G1 (46±11)×102 U/ml and G2(49×43)×102 U/ml were both significantly decreased than those of the control groups (99±42)×102 U/ml (P<0.05) and the difference between group G2 (36±15)×102 U/ml and the controls (68±32)×102 U/ml was statistically significant; ④The nephron crescent formation in group G1 (0.12±0.07) and G2 (0.08±0.02) was significantly lower that of the control group (0.20±0.06) (P<0.05) and that of group G2 was significantly less that of froup G1 (P<0.05); ⑤ The interstitial pneumonitis was singnificantly milder in group G1 than group G2. Conclusions UC- MSCs is very effective in treating MRL/lpr mice. It is safe and free of rejection reactions.